Diversify Wealth Management LLC Reduces Stock Holdings in Edwards Lifesciences Corporation $EW

Diversify Wealth Management LLC decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 91.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,910 shares of the medical research company’s stock after selling 42,906 shares during the period. Diversify Wealth Management LLC’s holdings in Edwards Lifesciences were worth $318,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of EW. Brighton Jones LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $266,000. NewEdge Advisors LLC grew its position in Edwards Lifesciences by 8.1% during the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. grew its position in Edwards Lifesciences by 16.7% during the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC increased its stake in Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina increased its stake in Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after purchasing an additional 1,065 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the transaction, the vice president directly owned 40,034 shares in the company, valued at approximately $3,671,117.80. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 45,577 shares of company stock valued at $3,855,527. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Down 2.4%

EW stock opened at $85.72 on Friday. The company has a market cap of $49.36 billion, a P/E ratio of 45.60, a P/E/G ratio of 2.15 and a beta of 0.86. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company’s 50-day moving average price is $87.34 and its 200 day moving average price is $83.94. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. TD Cowen reiterated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Truist Financial upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday. Evercore reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Finally, Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $98.95.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.